Ovarian Cancer Remission With Olaparib After Chemotherapy Intolerance

Patient Info: Anonymized, female, 50s | Stage III

Biomarkers: germline BRCA1 mutation

At 48 months, imaging showed complete remission and CA125 was normal while she continued reduced-dose olaparib.

PubMed CentralRead more →

I Was Told I Was TOO YOUNG For Breast Cancer!

Patient Info: Anonymized, Female | Stage IV

Metastatic Site: mediastinum; lymph nodes between the lungs

As of November 2025, the patient was living with Stage IV metastatic breast cancer, described as lifelong and requiring ongoing treatment. She had also completed local treatment for a later breast lesion.

YouTube — The Patient StoryRead more →

Stage I AR-positive triple-negative invasive apocrine breast carcinoma: disease-free after surgery, radiotherapy and chemotherapy

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: Triple-negative apocrine breast carcinoma with androgen receptor 90%

At 1-year follow-up, she remained disease-free with no clinical or radiologic evidence of recurrence.

PubMed CentralRead more →

Triple-negative breast cancer with pathologic complete response after neoadjuvant chemoimmunotherapy complicated by immune toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Left mastectomy on November 17 confirmed pathologic complete response, and 5-month follow-up showed no residual hepatic, dermatological, metabolic, or neurological sequelae from the treatment-related complications.

PubMed CentralRead more →

Synchronous primary squamous lung cancers: long disease control after multimodal therapy, then Stage IVA lung recurrence

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Squamous lung cancers with PD-L1 20% and no driver mutation detected; P40/P63 markers supported squamous type.

Metastatic Site: bilateral lung metastases at recurrence

As of November 2025, the patient had achieved 72 months of progression-free survival and remained alive at 75 months, but had developed Stage IVA recurrent pulmonary squamous cell carcinoma with bilateral lung metastases and had restarted systemic therapy.

PubMed CentralRead more →

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

HER2-positive breast cancer: brain recurrence, T-DXd liver injury, and later progression

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive; hormone receptor-negative; grade 3 infiltrative breast carcinoma

Metastatic Site: brain; thoracic lymph nodes

As of October 2025, the patient had developed brain and thoracic nodal recurrence after HER2-directed treatment, experienced T-DXd-associated liver injury, progressed after later paclitaxel/trastuzumab, and died at home in December 2024 under palliative care.

PubMed CentralRead more →

ALK-Fusion Gastric Cancer Responds to Alectinib Before Progression

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: DCTN1–ALK fusion; ATM p.E1724*; CDK6 amplification; HER2 negative; mismatch-repair proteins intact; later KRAS amplification

Metastatic Site: bone

Alectinib produced a partial response for about 11.5 months, but the cancer later progressed systemically and she died from uncontrollable gastrointestinal bleeding.

PubMed CentralRead more →

Stage IIIB HER2-positive breast cancer followed by resected pancreatic ductal adenocarcinoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: Breast cancer HER2-amplified; ER/PR changed from positive to negative after treatment. Pancreatic markers supported a separate pancreatic cancer.

The breast cancer achieved radiological and clinical remission after multimodality HER2-directed treatment. In 2025, a separate pancreatic ductal adenocarcinoma was resected, and adjuvant gemcitabine plus albumin-bound paclitaxel was recommended.

PubMed CentralRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

HER2-positive luminal B breast cancer with axillary tumor deposits: no recurrence after multimodal therapy

Patient Info: Anonymized, Female, 50s

Biomarkers: HER2-positive

After neoadjuvant therapy, mastectomy, axillary dissection, continued hormone therapy, and trastuzumab, she remained in good clinical condition with no detected recurrence.

PubMed CentralRead more →

Two Lung Cancer Patients Who Developed Bullous Pemphigoid During Pembrolizumab — Case 1

Patient Info: Anonymized, male, 70+

Biomarkers: PD-L1 TPS 5%

At the last follow-up, he was alive and continuing chemotherapy after later cancer progression, with no recurrence of bullous pemphigoid.

PubMed CentralRead more →

Stage IVA right lung squamous cell carcinoma: partial response complicated by camrelizumab-related pneumonitis and pulmonary bullae

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Squamous lung cancer marker profile: P40/CK5/6 positive, TTF-1/Napsin A negative. CEA/CYFRA tumor markers were elevated. PD-L1 not reported.

Metastatic Site: suspected pleural involvement / right pleural effusion

The cancer had a partial response to albumin-bound paclitaxel, carboplatin, and camrelizumab; camrelizumab was stopped after suspected immune-related pneumonitis, pulmonary embolism, and reversible pulmonary bullae, which improved after methylprednisolone was resumed.

PubMed CentralRead more →

Aggressive SMARCA4-deficient gastric cancer with rapid liver metastases after surgery

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: SMARCA4 loss; SMARCA4 frameshift mutation

Metastatic Site: liver

Multiple liver metastases appeared within 1 week after surgery. She received 1 chemotherapy cycle but could not continue because of poor condition and was transferred for hospice care.

PubMed CentralRead more →

Stage IIA male breast cancer: chemotherapy, mastectomy, endocrine therapy, and benign adrenal nodule

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Final breast cancer pathology was T1N1M0 / AJCC Stage IIA ER-positive, PR-positive, HER2-negative invasive ductal carcinoma; the suspicious adrenal lesion was removed in June 2025 and proved to be a benign adrenal adenoma.

PubMed CentralRead more →

Small-cell lung cancer with anti-NMDAR encephalitis: neurologic recovery and cancer care ongoing

Patient Info: Anonymized, Male, 70+

Biomarkers: Anti-NMDAR antibodies positive in cerebrospinal fluid; tumor molecular markers not reported

He recovered without significant neurologic sequelae and had no recurrence of neuropsychiatric symptoms; SCLC treatment with carboplatin and paclitaxel began after discharge, and cancer remission status was not documented.

PubMed CentralRead more →

Triple-negative breast cancer history with later chest wall sarcomatoid carcinoma treated by embolization, ablation, and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Initial breast cancer was triple-negative. Later chest-wall lesion was weak ER-positive, PR/HER2-negative

By February 2025, the treated chest wall lesion had decreased to about 13 x 7 mm after embolization, radiofrequency ablation, and albumin-bound paclitaxel plus cisplatin, with no peripheral or distant metastatic foci seen.

PubMed CentralRead more →

Stage IIIB male encapsulated papillary breast cancer: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: ER-positive 100%; PR-positive 100%; HER2-negative / IHC 1+; p63 loss supported encapsulated papillary carcinoma; no neuroendocrine differentiation

Three years after diagnosis, he was clinically doing well without evidence of breast cancer recurrence after mastectomy, radiation, and tamoxifen.

PubMed CentralRead more →

Triple-negative node-positive breast cancer with complete pathologic response and benign nodal nevi

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer; BRCA testing negative. Axillary melanocytic cells looked benign.

Pathology showed complete response in the breast, no residual breast carcinoma in the sampled specimen, and axillary nodal melanocytic proliferations interpreted as benign nodal nevi rather than metastatic melanoma or breast carcinoma.

PubMed CentralRead more →

Metastatic lung adenocarcinoma with HER2 V659E/amplification responding to trastuzumab deruxtecan

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial lung testing showed no EGFR/ALK/ROS1 and PD-L1 TPS 3%. Later biopsy found HER2 V659E plus HER2 amplification.

Metastatic Site: liver, bone, brain

As of September 2024, metastatic lung adenocarcinoma had a sustained partial response to trastuzumab deruxtecan after HER2 V659E mutation and HER2 amplification were identified.

PubMed CentralRead more →

Synchronous triple-negative breast cancer and rectal adenocarcinoma complicated by hepatitis B reactivation

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer with pathogenic BRCA1 mutation; hepatitis B reactivation occurred during treatment.

At 3-year follow-up, she remained healthy and disease-free after treatment for synchronous triple-negative breast cancer and mid-rectal adenocarcinoma, with hepatitis B reactivation controlled on entecavir.

PubMed CentralRead more →

Stage IB pancreatic adenocarcinoma with lung and pleural recurrence: long-term disease control on chemotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Metastatic pancreatic cancer in lung: CK19/MUC1/CA19-9-positive, TTF-1-negative. UGT1A1 *6 heterozygous; no actionable mutation found.

Metastatic Site: lung, pleura

As of April 2025, he remained alive on chemotherapy 6 years and 8 months after initial pancreatic surgery and 4 years and 7 months after pulmonary oligometastatic recurrence, with no new lesions and stable disease on imaging.

PubMed CentralRead more →

Metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: HER2-positive breast cancer. Jaw workup focused on osteonecrosis

Metastatic Site: bone / osseous metastasis

The case focused on metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw after antiresorptive therapy; dental pain improved transiently after oral-surgery interventions, but systemic cancer response was not described.

PubMed CentralRead more →

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →